Published online Oct 27, 2022. doi: 10.4240/wjgs.v14.i10.1120
Peer-review started: June 24, 2022
First decision: August 1, 2022
Revised: August 19, 2022
Accepted: September 22, 2022
Article in press: September 22, 2022
Published online: October 27, 2022
Hemorrhoids are a common anal condition and can afflict an individual at any age. Cap-assisted endoscopic sclerotherapy (CAES) is a novel procedure to process flexible endoscopic sclerotherapy.
There are few previous studies discussing CAES in the treatment of internal hemorrhoids with large sample size and long-term follow-up, so this study can make up for the shortcomings of previous theories.
Long-term efficacy and safety of CAES with long injection needle for internal hemorrhoids were assessed.
This retrospective analysis of data from patients with symptomatic internal hemorrhoids treated with CAES using endoscopic long injection needle from April 2016 to December 2019 were collected. Patients were telephoned and followed at two time points, December 2020 and 2021, to evaluate the impro
Two hundred and one patients with internal hemorrhoids underwent CAES with the long needle, At the first follow-up, 62.7% of patients had both improved hemorrhoid grades and symptoms, and 27.4% had a significant improvement in both parameters. At the second follow-up, 61.7% of the patients showed satisfactory improvement in their hemorrhoid grade and symptoms when compared with pre-surgery values. 90% of patients reported CAES was painless, and 85% were satisfied/very satisfied with CAES treatment outcomes.
The present study based on the largest sample size reported the long-term follow-up of the treatment for internal hemorrhoid with the CAES using endoscopic long injection needle. Our findings demonstrate that CAES should be a micro-invasive endoscopic technology yields satisfactory long-term efficacy and safety.
The improvement of symptoms, complications, recurrence and satisfaction of patients with symptomatic hemorrhoids were cure by CAES.